EXCEED THE SPACE PROVIDED. The Notch signal transduction pathway controls cell fate decisions important for neurogenesis and hematopoesis, and is misregulated in human cancers. Signaling results in the proteolytic release of the intraeellular domain (ICD) of the Notch receptor, a dedicated transcriptional co-activator of CSL enhancer- binding proteins. Our lab recently developed a chromatin-based system that recapitulates Notch transcription in vitro. We show that the ICD lacks an intrinsic activation domain, but rather recruits Mastermind (MAM), which provides two distinct regulatory domains. A MAM chromatin-specific activation domain recn_ts the CBP/p300 histoneacetyltransferase. The second activation domain, which is essential for Notch transcription in vivo, also serves to couple Notch transcription to modification and proteolytic turnover of the ICD within,the Notch enhancer. This region of the MAM also mobilizes CBP/p300 to nuclear inclusion bodies similar to those formed by mutant polyglutamine-repeat proteins in neurodegenerative diseases. These findings indicate that MAM is a novel transcriptional regulator which : functions to couple activation to turnover, ensuring that the Notch enhancer complex is short-lived. We plan to further define the Notch regulatory mechanism through the following alms: 1) Analyze the mechanisms that regulate initiation and elongation of Notch transcription on chromatin templates and identify the protein(s) that interact with the MAM activation domains; 2) Assess the process by which MAM induces the formation of nuclear inclusion bodies, determine the composition of these structures and assess connections to the ubiquitination-proteolysis machinery; 3) Analyze the role of MAM in the proteolytic turnover of the Notch ICD. We will identify the nuclear kinase that phosphorylates the ICD and detenmne if the Sel-10 ubiqutin ligase is recruited to the Notch enhancer; and 4) Characterize the structure and mode of regulation of a natural (periodic) Notch enhancer in the cell-free in vitro transcription system. These studies we help elucidate the Notch transactivation mechanism and its role in the modification and destruction of the ICE), and may suggest approaches for blocking Notch signaling in human cancers. PERFORMANCE SITE ========================================Section End===========================================

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM067127-03
Application #
6835201
Study Section
Cell Development and Function Integrated Review Group (CDF)
Program Officer
Tompkins, Laurie
Project Start
2003-01-01
Project End
2006-12-31
Budget Start
2005-01-01
Budget End
2005-12-31
Support Year
3
Fiscal Year
2005
Total Cost
$460,110
Indirect Cost
Name
Salk Institute for Biological Studies
Department
Type
DUNS #
078731668
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Baird, Nicholas L; Yu, Xiaoli; Cohrs, Randall J et al. (2013) Varicella zoster virus (VZV)-human neuron interaction. Viruses 5:2106-15
Jones, Katherine A (2011) A SirT'N repression for Notch. Mol Cell 42:559-60
Jones, Katherine A (2009) Outsmarting a mastermind. Dev Cell 17:750-2
Sierra, Jose; Yoshida, Tomonori; Joazeiro, Claudio A et al. (2006) The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev 20:586-600
Fryer, Christy J; White, J Brandon; Jones, Katherine A (2004) Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell 16:509-20